Phase I/II study of BMS-986156 with ipilimumab or nivolumab with or without stereotactic ablative radiotherapy in patients with advanced solid malignancies
2024; BMJ; Volume: 12; Issue: 10 Linguagem: Inglês
10.1136/jitc-2024-009975
ISSN2051-1426
AutoresJoe Y. Chang, Xinyan Xu, Girish S. Shroff, Nathan I Comeaux, Wei Li, Jordi Rodón, Daniel D. Karp, Ecaterina E. Dumbrava, Vivek Verma, Aileen B. Chen, James W. Welsh, David S. Hong,
Tópico(s)Advanced Radiotherapy Techniques
ResumoBMS-986156 is an agonist of the glucocorticoid-induced tumor necrosis factor receptor (TNFR)-related protein (GITR) and promotes increased effector T-cell activation. Combined anti-GITR, anti-programmed death-1, anti-cytotoxic T-lymphocyte-associated protein 4 antibodies and radiotherapy improve tumor control in preclinical studies. Herein we describe the results of the safety and efficacy of BMS-986156+ipilimumab or nivolumab with/without stereotactic ablative radiotherapy (SABR) in patients with advanced solid cancers (NCT04021043).
Referência(s)